Lippis Daniel J.'s Form 4 filing
Edwards Lifesciences Corp (EW) · filed Mar 11, 2026
- Accession no.
- 0001225208-26-003538
- Filed
- Mar 11, 2026
- Trade date
- Mar 11, 2026
- Filing delay
- Same day
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $87.0K. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lippis Daniel J.CIK 0002004380 | Officer (CVP, TAVR) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 11, 2026 | Common Stock | MOption exerciseAcquired | +1,019 | $59.26 | +$60,385.94 | 34,952.91 | Direct | |
| Mar 11, 2026 | Common Stock | SSaleDisposed | −1,019 | $85.38F2 | −$87,002.22 | 33,933.91 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 11, 2026 | Common Stock | MOption exerciseDisposed | −1,019 | $0.00 | $0 | 3,057 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $85.16 to $85.76. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide,uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
Remarks
This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.